摘要
虽然以免疫检查点抑制剂为代表的的免疫治疗为部分恶性肿瘤患者带来了生存获益,但仍存在不容忽视的问题,其中免疫治疗的低应答率限制了其临床应用。近年来,肠道菌群越来越被认为是免疫治疗疗效的重要预测性生物标志物之一,对肿瘤免疫微环境的调节是其重要的作用机制。中医药是我国补充医学的代表,口服中药对肠道菌群具有调节作用,其对于肿瘤免疫微环境的改善和免疫治疗疗效的提高也被肿瘤学界高度关注。本文将基于肠道菌群总结并探讨中医药调节肿瘤免疫微环境而提高免疫治疗疗效的研究现状,以期为中医药与免疫治疗协同增效提供理论依据,为进一步基础和临床研究提供思路。
Although immunotherapy,represented by immune checkpoint inhibitors,has brought survival benefits to some patients with malignant tumours,there are still problems that should not be ignored,among which the low response rate of immunotherapy limits its clinical application.In recent years,gut microbiota is increasingly considered as one of the important predictive biomarkers of immunotherapy efficacy,and the regulation of the tumour immune microenvironment is one of the important mechanisms of action.Traditional Chinese medicine(TCM) is a representative of complementary medicine in China,and oral TCM has a regulatory effect on gut microbiota,and its improvement of the tumour immune microenvironment and the efficacy of immunotherapy is also highly concerned by the oncology community.Based on the gut microbiota,this paper will summarise and discuss the current status of research on the regulation of the tumour immune microenvironment by TCM to improve the efficacy of immunotherapy,with a view to providing a theoretical basis for the synergistic effect of TCM and immunotherapy,and providing ideas for further basic and clinical research.
作者
毛启远
樊慧婷
王学谦
蒋伶俐
张鹏
李道睿
林洪生
MAO Qiyuan;FAN Huiting;WANG Xueqian;JIANG Lingli;ZHANG Peng;LI Daorui;LIN Hongsheng(Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Department of TCM Rehabilitation,Shangdang District People's Hospital,Changzhi city,Shanxi Changzhi 047100,China)
出处
《现代肿瘤医学》
CAS
2024年第5期958-962,共5页
Journal of Modern Oncology
基金
国家自然科学基金面上项目(编号:82074405)
国家中医药管理局2013年度中医药行业科研专项项目(编号:201307006)。
关键词
肠道菌群
中医药
肿瘤免疫微环境
免疫治疗
研究现状
gut microbiota
traditional Chinese medicine
tumour immune microenvironment
immunotherapy
re-search status
